Breaking News

Financial Report: Alexion

February 3, 2016

Strensiq launched in the quarter, Soliris sales up 15%


4Q Revenues: $701 million (-17%)
4Q Earnings: $66.6 million (-57%)
FY Revenues: $2.6 billion (+21%)
FY Earnings: $144.4 million (earnings were $657 million FY14)
Comments: Soliris sales were $689 million in the quarter, up 15%. For the year, Soliris sales were $2.6 billion, up 21%. Strensiq sales were $11.6 million in the quarter and $12 million for the year. Strensiq was approved by the FDA for the treatment of perinatal-, infantile- and juvenile-onset hypophosphatasia (HPP) in 4Q15. R&D expenses were $191 million, up 48%.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks